Trial Search Results
Localized Therapeutics for the Treatment of Gastrointestinal Disorders
The purpose of this study is to determine the patient preference for a biocompatible thermosensitive solution-gel versus water or saline (liquid) enema. The thermosensitive solution-gel is comprised of poloxamer, an inactive compound that is designated as GRAS (generally recognized as safe) by FDA. It could subsequently be used as a medium for drug delivery. The poloxamer (gel) is administered to study participants in order to assess preference and proximal distribution.
Stanford is currently accepting patients for this trial.
- Other: Thermosensitive gel rectal formulation
- Other: Saline enema
- Generally healthy
- Age 18 to 70 years old
- GI complaints
- Patients with previous colonic surgery or current bowel injury or obstruction
- Allergies to contrast
Ages Eligible for Study
18 Years - N/A
Genders Eligible for Study